Your search for smoking cessation returned 166 results

For individuals who have quit smoking, use of nicotine replacement therapy (NRT) may not impact relapse rates.

The FDA has notified the public that the smoking cessation aid Chantix (varenicline; Pfizer) may be associated with a small, increased risk of certain cardiovascular events in patients with cardiovascular disease.

Orexigen Therapeutics announced positive results from its Phase 2b trial for Empatic (bupropion SR/zonisamide SR), its investigational combination drug for the treatment of obesity.

The FDA has approved Watson’s over-the-counter nicotine polacrilex gum in coated fruit and cinnamon flavors, the generic equivalent of GlaxoSmithKline Consumer Healthcare’s smoking cessation aid, Nicorette Fruit Chill and Cinnamon Surge Coated gums.

The FDA has notified healthcare professionals and patients that it has required manufacturers of varenicline (Chantix, from Pfizer) and bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL, and Zyban, from GlaxoSmithKline) to add new Boxed Warnings to the product labeling and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms.

The labeling for Chantix (varenicline tartrate, from Pfizer) has been updated with a warning to observe patients for serious neuropsychiatric symptoms, including changes in behavior, agitation, depressed mood, suicidal ideation and suicidal behavior.